Company / EPS (Diluted)
Rapport Therapeutics, Inc. EPS (Diluted) History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.78
FY2024
5-year range
-$23.10 / -$3.78
FY2023-FY2024
Trend
+83.6%
vs FY2023
Sector context
#159 of 204
Health Care
What the data says
Rapport Therapeutics, Inc.'s eps (diluted) of $-3.78 is lower than 78% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
-3.78 in FY2024.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 204This company -$3.78 Sector average -$0.89
▼
-322.4% below sector average
Key checks
Key Insights
- In FY2024, eps (diluted) increased 83.6% year-over-year.
- Ranks #159 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$3.78 | +83.6% |
| FY2023 | -$23.10 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026